Before CJC-1295 and the newer generation of growth hormone secretagogues, there was sermorelin. As the first synthetic GHRH analogue to achieve FDA approval and accumulate substantial clinical research, sermorelin bridges the gap between established clinical medicine and the broader world of peptide research.
What Is Sermorelin?
Sermorelin (GHRH(1-29)) is a synthetic analogue of Growth Hormone Releasing Hormone comprising the first 29 amino acids of native 44-amino acid GHRH. This fragment retains full biological activity at GHRH receptors on pituitary somatotroph cells. Originally approved by the FDA as Geref for GH deficiency treatment in children, it has one of the strongest clinical research foundations of any GHRH analogue.
How Sermorelin Works
Sermorelin binds GHRH receptors on pituitary somatotrophs, increasing intracellular cAMP, triggering GH synthesis and release, stimulating pituitary cell proliferation, and elevating downstream IGF-1. Unlike exogenous HGH, sermorelin stimulates the body’s own pituitary to produce GH — preserving natural feedback loops including somatostatin-mediated negative feedback.
Clinical and Research Evidence
Pediatric GH Deficiency: Clinical trials demonstrated significant increases in linear growth velocity, elevated GH and IGF-1 levels, and comparable efficacy to direct rhGH administration in some trial arms, with a favorable long-term safety profile.
Adult Anti-Aging Research: Studies targeting the somatopause (age-related GH/IGF-1 decline) showed increased GH pulse amplitude, elevated IGF-1, improved body composition (increased lean mass, reduced fat), enhanced slow-wave sleep (when most natural GH secretion occurs), and improved energy and well-being in subjects.
Pituitary Preservation Advantage: Long-term exogenous GH can downregulate pituitary production. Sermorelin may actually stimulate pituitary cell proliferation over time — potentially increasing the pituitary’s capacity for GH production.
Sermorelin vs. CJC-1295
| Feature | Sermorelin | CJC-1295 |
|---|---|---|
| Amino acids | 29 | 30 (modified) |
| Half-life | ~10–20 minutes | 30 min (no DAC) / 6–8 days (DAC) |
| FDA history | Approved (Geref, discontinued 2008) | Never FDA approved |
| Clinical research depth | Substantial (pediatric + adult) | Phase I/II human trials |
Conclusion
Sermorelin’s clinical track record, established safety profile, and unique pituitary-preserving mechanism make it one of the most important reference compounds in GHRH research. Combat Research offers research-grade sermorelin verified to pharmaceutical purity standards.
For research purposes only. Not for human therapeutic use.
Related Research Articles
Shop Sermorelin at Combat Research
Research-grade Sermorelin 10mg at ≥99% purity. USA domestic sourcing, same-day shipping on in-stock orders.
